Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs).

Ther Adv Musculoskelet Dis · 2022 · PMC9128067 · PMID 35619876

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

122 A 1-year phase III trial revealed a reduction in pain of 25% with TG-C treatment compared with 10% with the placebo group and no significant structural benefits on the JSN and MRI outcomes as the secondary endpoints ( n = 163), 123 despite exhibiting a clear trend towards slower bone area progression in the TG-C group.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.